Research Article| Volume 152, ISSUE 1, P86-90, September 2010

Efficacy and safety of aceclofenac and drotaverine fixed-dose combination in the treatment of primary dysmenorrhoea: a double-blind, double-dummy, randomized comparative study with aceclofenac



      To evaluate the efficacy and safety of aceclofenac–drotaverine combination against aceclofenac alone in patients with primary dysmenorrhoea.

      Study design

      This double-blind, double-dummy, randomized, comparative, multicentric study enrolled 200 women (100 women in each arm) in the age range of 18–35 years with primary dysmenorrhoea at four centers. The patients were randomly allocated to either aceclofenac 100 mg–drotaverine 80 mg b.i.d or aceclofenac 100 mg alone b.i.d for a maximum of 3 days. Primary efficacy parameters were total area under pain relief (PR) score up to 4 and 8 h (TOPAR/4 and TOPAR/8). Secondary efficacy measurements were pain-intensity difference (PID), sum of PID over 4 and 8 h (SPID/4 and SPID/8), peak PID over 4 and 8 h and peak PR over 4 and 8 h, total study drug consumption, and patient's and investigator's global evaluation of the efficacy.


      Both treatments showed significant improvement in baseline values in all efficacy parameters. The combination was significantly superior to monotherapy in terms of TOPAR/4 (24.0 vs 18.54) (p = 0.000) and TOPAR/8 (40.3 vs 35.2) (p = 0.003), SPID/4 (−17.9 vs −13.88) (p = 0.000) and SPID/8 (−31.06 vs −26.8) (p = 0.001), peak PID/4 (−6.60 vs −5.75) (p = 0.001) and peak PR/4 (8.26 vs 7.10) (p = 0.000). At the end of 8 h, both treatments were comparable with respect to peak PID/8 and peak PR/8 (p > 0.05). The total number of doses consumed by patients treated with combination therapy was less than with monotherapy (150 vs 168 doses). The combination was significantly superior to monotherapy with respect to patient's and investigator's global evaluation of the efficacy (p = 0.002 and p = 0.001, respectively). Both treatments were well tolerated.


      This study establishes the efficacy of aceclofenac–drotaverine combination in patients with primary dysmenorrhoea. The fixed-dose combination of aceclofenac and drotaverine should therefore be considered as a suitable, effective and well tolerated treatment option for primary dysmenorrhoea.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


        • Dawood M.Y.
        J Reprod Med. 1985; 30: 154-167
        • Letzel H.
        • Megard Y.
        • Lamarca R.
        • Raber A.
        • Fortea J.
        The efficacy and safety of aceclofenac versus placebo and naproxen in women with primary dysmenorrhoea.
        Eur J Obst Gynecol Reprod Biol. 2006; 129: 162-168
        • Lundstrom V.
        Treatment of primary dysmenorrhoea with prostaglandin synthetase inhibitors—a promising therapeutic alternative.
        Acta Obstet Gynecol Scand. 1978; 57: 421-428
        • Morrison B.
        • Daniels S.
        • Kotey P.
        • Cantu N.
        • Seidenberg B.
        Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhoea: a randomized, controlled trial.
        Obstet Gynecol. 1999; 94: 504-508
        • Chan W.Y.
        • Fuchs F.
        • Powell A.M.
        Effects of naproxen sodium on menstrual prostaglandins and primary dysmenorrhoea.
        Obstet Gynecol. 1983; 61: 285-291
        • Claudette A.
        • Lotte B.
        • Jean B.
        • Tamsin C.
        Preservex tablets: pharmacological and pharmacokinetic propertie.
        ABPI, Medicines Compendium. 2002; : 1594
        • Lemmel E.
        • Leeb B.
        • Bast J.
        • Aslanidis S.
        Patient and physician satisfaction with aceclofenac: results of the European observational cohort study (experience with aceclofenac for inflammatory pain in daily practice).
        Curr Med Res Opin. 2002; 18: 146-153
        • Pap A.
        • Topa L.
        • Balgha V.
        • Kovats-Megyesi A.
        • Pozsar J.
        • Szikszai E.
        Drotaverine antagonizes spasm of Oddi's sphincter provoked by morphine in man.
        Gastroenterology. 1997; 112: A519
        • Bolaji O.O.
        • Onyeji C.O.
        • Ogunaini A.O.
        • Olugbade T.A.
        • Ogunbona F.
        Pharmacokinetics and bioavailability of drotaverine in humans.
        Eur J Drug Metab Pharmacokinet. 1996; 21: 217-221
        • John T.
        • James P.
        • Linda L.
        • John L.R.
        • Michael P.
        Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
        Pain. 2001; 94: 149-158
        • Romics I.
        • Molnar D.L.
        • Timberg G.
        • et al.
        The effect of drotaverine hydrochloride in acute colicky pain caused by renal and ureteric stones.
        BJU Int. 2003; 92: 92-96